Role of Gene Therapy in Treating Heart Failure

Abstract

Heart failure (HF) is a complex and debilitating syndrome with high mortality and morbidity rates, posing a significant global health challenge. Despite advancements in medical and device therapies, outcomes remain suboptimal, underscoring the urgent need for novel therapeutic strategies. Gene therapy has emerged as a promising frontier in HF treatment, offering the potential to address the underlying molecular and cellular abnormalities that drive disease progression. This review provides a comprehensive overview of the current landscape of gene therapy for HF, encompassing various gene targets, delivery systems, and preclinical and clinical studies. We discuss the rationale behind targeting specific genes involved in cardiac contractility, calcium handling, angiogenesis, and inflammatory pathways. Furthermore, we explore the challenges and opportunities associated with different viral and non-viral gene delivery vectors, emphasizing their respective advantages and limitations. Recent clinical trials have demonstrated the feasibility and safety of gene therapy in HF patients, with some showing encouraging signs of improved cardiac function and clinical outcomes. However, several hurdles remain, including optimizing gene transfer efficiency, ensuring long-term gene expression, and mitigating potential immunogenicity. Future directions in gene therapy for HF involve the development of more potent and specific gene constructs, combination therapy approaches, and personalized medicine strategies. As our understanding of HF pathophysiology deepens and gene editing technologies advance, gene therapy holds immense promise to revolutionize the management of this devastating condition, moving beyond symptomatic relief to offer disease-modifying interventions.